Publications

• A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV
  SELENT, U., RUTER, T., Kohler, E., Liedtke, M., THIELKING, V., Alves, J., … Pingoud, A. (1992). A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV. BIOCHEMISTRY, 31(20), 4808–4815.
• Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
  Liedtke, M., Hamlin, P. A., Moskowitz, C. H., & Zelenetz, A. D. (2006). Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. ANNALS OF ONCOLOGY, 17(6), 909–913.
• Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
  Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., & Medeiros, B. (2008). Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. LEUKEMIA & LYMPHOMA, 49(3), 581–85.
• Therapeutic targeting of MLL Liedtke, M., & Cleary, M. L. (2009). Therapeutic targeting of MLL. BLOOD, 113(24), 6061–68.
  
• Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6 Liedtke, M., Ayton, P. M., Somervaille, T. C. P., Smith, K. S., & Cleary, M. L. (2010). Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. BLOOD, 116(1), 63–70.
  
• Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., … Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877–81.
  
• Plasma cell leukemia: concepts and management. Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. Expert Review of Hematology, 3(5), 543–49.
  
• Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., … Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30–37.
  
• Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., … Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893–901.
  
• Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2012). Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 31(3), 325–31.
  
• The Transcription Factor Encyclopedia Yusuf, D., Butland, S. L., Swanson, M. I., Bolotin, E., Ticoll, A., Cheung, W. A., … Wasserman, W. W. (2012). The Transcription Factor Encyclopedia. GENOME BIOLOGY, 13(3).
  
• More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., Schrier, S., … Liedtke, M. (2012). More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 138(5), 509–11.
  
• Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., … Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957–60.
  
• Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Hematology (Amsterdam, Netherlands).
  
• Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., … Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591–96.
  
• Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., … Kumar, R. (2013). Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(1), 11–17.
  
• A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Patel, S., Liedtke, M., Ngo, D., & Medeiros, B. C. (2013). A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Leukemia & Lymphoma, 54(10), 2231–35.
  
• The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., … Liedtke, M. (2013). The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(3), 367–72.
  
• Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., … Liedtke, M. (2013). Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica, 98(10), 1593–99.
  
• AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., Baranczak, A., … Alhamadsheh, M. M. (2013). AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(24), 9992–97.
  
• Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase Liedtke, M., Pandey, P., Kumar, S., KHARBANDA, S., & Kufe, D. (1998). Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. ONCOGENE, 17(15), 1889–1892.
  
• Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21).
  
• Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2011). Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy. JOURNAL OF CARDIAC FAILURE, 17(8), S45–S46.
  
• Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., … Witteles, R. M. (2014). Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. HEART RHYTHM, 11(1), 158–62.
  
• Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. Ohgami, R. S., Sendamarai, A. K., Atwater, S. K., Liedtke, M., Fleming, M. D., Natkunam, Y., & Warnke, R. A. (2014). Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. American Journal of Surgical Pathology, 38(9), 1298–1304.
  
• Effects of serum and plasma matrices on multiplex immunoassays. Rosenberg-Hasson, Y., Hansmann, L., Liedtke, M., Herschmann, I., & Maecker, H. T. (2014). Effects of serum and plasma matrices on multiplex immunoassays. Immunologic Research, 58(2-3), 224–33.
  
• Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia Dinner, S., Lee, D., & Liedtke, M. (2014). Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 55(8), 1715–24.
  
• Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441–45.
  
• Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., … Witteles, R. M. (2015). Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. American Journal of Transplantation , 15(3), 650–58.
  
• Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leukemia & Lymphoma, 57(3), 609–15.
  
• Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma Hansmann, L., Blum, L., Ju, C.-H., Liedtke, M., Robinson, W. H., & Davis, M. M. (2015). Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma. CANCER IMMUNOLOGY RESEARCH, 3(6), 650–60.
  
• CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Iwasaki, M., Liedtke, M., Gentles, A. J., & Cleary, M. L. (2015). CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Cell Stem Cell, 17(4), 412–21.
  
• Multiple Myeloma, Version 2.2016 Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2015). Multiple Myeloma, Version 2.2016. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(11), 1398–1435.
  
• A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59.
  
• First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Gertz, M. A., Landau, H., Comenzo, R. L., Seldin, D., Weiss, B., Zonder, J., … Liedtke, M. (2016). First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology , 34(10), 1097–1103.
  
• Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature. Leatham, H. W., Novoa, R., Liedtke, M., & Kwong, B. Y. (2016). Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature. Clinical Lymphoma, Myeloma & Leukemia, 16(1), e1–5.
  
• Identification of Doxorubicin as an Inhibitor of the IRE1a-XBP1 Axis of the Unfolded Protein Response. Jiang, D., Lynch, C., Medeiros, B. C., Liedtke, M., Bam, R., Tam, A. B., … Koong, A. C. (2016). Identification of Doxorubicin as an Inhibitor of the IRE1a-XBP1 Axis of the Unfolded Protein Response. Scientific Reports, 6, 33353-?
  
• Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., … Advani, A. S. (2016). Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 375(8), 740–53.
  
• Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2016). Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(4), 389–400.
  
• Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., … Kumar, R. (2017). Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(2), 230-?
  
• Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. DeAngelo, D. J., George, T. I., Linder, A., Langford, C., Perkins, C., Ma, J., … Gotlib, J. (2017). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia.
  
• Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry). Tuzovic, M., Kobayashi, Y., Wheeler, M., Barrett, C., Liedtke, M., Lafayette, R., … Witteles, R. (2017). Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry). The American Journal of Cardiology, 120(8), 1381–86.
  
• Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2018). Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leukemia Research, 67, 17–20.
  
• NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY Liedtke, M., Comenzo, R., Landau, H., Sanchorawala, V., Weiss, B., Zonder, J., … Gertz, M. (2017). NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 69(11), 825.
  
• NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response Liedtke, M. M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response. EUROPEAN JOURNAL OF HEART FAILURE, 19, 441.
  
• A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis Cohen, A. D., Scott, E. C., Liedtke, M., Kaufman, J. L., Landau, H., Vesole, D. H., … Durie, B. G. M. (2014). A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. BLOOD, 124(21).
  
• Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016 Maurer, M., Lousada, I., Hanna, M., Ruberg, F., Mohty, D., Dispenzieri, A., … Grogan, M. (2017). Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 24, 165–66.
  
• Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2015). Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia. BLOOD, 126(23).
  
• The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. Liedtke, M., Merlini, G., Landau, H. J., Comenzo, R., Seldin, D. C., Weiss, B. M., … Gertz, M. A. (2015). The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2016). NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study. EUROPEAN HEART JOURNAL, 37, 220.
  
• Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow Hansmann, L., Han, A., Penter, L., Liedtke, M., & Davis, M. M. (2017). Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow. CANCER IMMUNOLOGY RESEARCH, 5(9), 744–54.
  
• NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., … Shead, D. A. (2018). NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(1), 11–20.
  
• Clinical implications of gastrointestinal symptoms in systemic amyloidosis Yen, T., Chen, F. W., Witteles, R. M., Liedtke, M., & Nguyen, L. A. (2018). Clinical implications of gastrointestinal symptoms in systemic amyloidosis. NEUROGASTROENTEROLOGY AND MOTILITY, 30(4), e13229.
  
• NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response. ONCOLOGY RESEARCH AND TREATMENT, 40, 34–35.
  
• NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY Gertz, M., Comenzo, R. L., Landau, H., Sanchorawala, Weiss, B. M., Zonder, J. A., … Liedtke, M. (2017). NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 22(3), 289–90.
  
• Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE Jabbour, E. J., DeAngelo, D. J., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., … Kantarjian, H. M. (2018). Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE. CANCER, 124(8), 1722–32.
  
• Novel therapeutic approaches for AL amyloid Liedtke, M. (2017). Novel therapeutic approaches for AL amyloid. ONCOLOGY RESEARCH AND TREATMENT, 40, 194.
  
• Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., … Advani, A. S. (2017). Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. BLOOD ADVANCES, 1(15), 1167–80.
  
• Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., & Liedtke, M. (2017). Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. BLOOD, 130(7), 900–902.
  
• Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response Saygin, C., Papadantonakis, N., Cassaday, R. D., Liedtke, M., Fischer, K., Dunn, T., … Advani, A. S. (2018). Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. LEUKEMIA & LYMPHOMA, 59(2), 363–71.
  
• A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Dinner, S., Dunn, T. J., Price, E., Coutré, S. E., Gotlib, J., Berube, C., … Liedtke, M. (2018). A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International Journal of Hematology.
  
• Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients. Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., & Dunn, T. (2018). Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients. Journal of Adolescent and Young Adult Oncology.
  
• Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma Richardson, P. G., Hofmeister, C. C., Rosenbaum, C. A., Htut, M., Vesole, D. H., Berdeja, J. G., … Baz, R. (2018). Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 182(2), 231–44.
  
• Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia Yurkiewicz, I. R., Muffly, L., & Liedtke, M. (2018). Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. DRUG DESIGN DEVELOPMENT AND THERAPY, 12, 2293–2300.
  
• Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis Yen, T., Chen, F., Witteles, R., Liedtke, M., & Nguyen, L. A. (2017). Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis. AMERICAN JOURNAL OF GASTROENTEROLOGY, 112, S240.
  
• Antibody-based therapies in patients with acute lymphoblastic leukemia. Dinner, S., & Liedtke, M. (2018). Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematology. American Society of Hematology. Education Program, 2018(1), 9–15.
  
• Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis. Gong, C. L., Studdert, A. L., & Liedtke, M. (2018). Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis. American Journal of Hematology.
  
• Grading cardiac response in AL amyloidosis: implications for relapse and survival. Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2018). Grading cardiac response in AL amyloidosis: implications for relapse and survival. British Journal of Haematology.
  
• Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Jabbour, E., Advani, A. S., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., … Kantarjian, H. M. (2019). Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology.
  
• A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): Final Results of Alliance/CALGB Study 10701 Wieduwilt, M. J., Yin, J., Wetzler, M., Uy, G. L., Powell, B. L., Kolitz, J. E., … Larson, R. A. (2018). A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): Final Results of Alliance/CALGB Study 10701. BLOOD, 132.
  
• Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse Aleshin, A., Durruthy-Durruthy, R., Corces, M. R., Stafford, M., Liedtke, M., Medeiros, B. C., … Majeti, R. (2018). Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse. BLOOD, 132.
  
• Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., … Costa, L. J. (2019). Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia.
  
• Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., … Advani, A. S. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer.
  
• Contemporary Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation Alexander, K., Barrett, C., Dobos, K., Cheng, P., Liao, R., Wheeler, M., … Witteles, R. (2019). Contemporary Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 38(4), S215.
  
• Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Chung, A., & Liedtke, M. (2019). Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Best Practice & Research. Clinical Haematology, 32(1), 54–64.
  
• A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., … Larson, R. A. (2019). A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. BLOOD, 133(14), 1548–59.
  
• Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., … Kochenderfer, J. N. (2019). Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. NEW ENGLAND JOURNAL OF MEDICINE, 380(18), 1726–37.
  
• B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma Eckhert, E., Hewitt, R., & Liedtke, M. (2019). B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma. IMMUNOTHERAPY, 11(9), 801–11.
  
• Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., & Dunn, T. (2018). Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients. JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 7(5), 579–83.
  
• Grading cardiac response in AL amyloidosis: implications for relapse and survival Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2019). Grading cardiac response in AL amyloidosis: implications for relapse and survival. BRITISH JOURNAL OF HAEMATOLOGY, 186(1), 144–46.
  
• Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Goekbuget, N., … Advani, A. S. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. CANCER, 125(14), 2474–87.
  
• Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., … Costa, L. J. (2019). Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. LEUKEMIA, 33(9), 2266–75.
  
• Outcome of relapsed or refractory acute lymphoblastic leukemia patients with extramedullary disease or lymphoblastic lymphoma receiving inotuzumab ozogamicin or standard care in the INO-VATE trial Marks, D. I., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., … Kantarjian, H. (2019). Outcome of relapsed or refractory acute lymphoblastic leukemia patients with extramedullary disease or lymphoblastic lymphoma receiving inotuzumab ozogamicin or standard care in the INO-VATE trial. BONE MARROW TRANSPLANTATION, 54, 149–51.
  
• A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis. Barrett, C. D., Dobos, K., Liedtke, M., Tuzovic, M., Haddad, F., Kobayashi, Y., … Witteles, R. M. (2019). A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis. JACC. Heart Failure.
  
• Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection Aleshin, A., Durruthy-Durruthy, R., Corces, R., Liedtke, M., Eastburn, D., & Majeti, R. (2019). Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection. CANCER RESEARCH, 79(13).
  
• Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines Kumar, S. K., Callender, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., … Kumar, R. (2019). Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(10), 1155–65.
  
• Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM) Cornell, R., Parameswaran, H., Tang, S., Barnstead, A., Biran, N., Callander, N., … Costa, L. (2019). Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19(10), E115–E116.
  
• Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. Granja, J. M., Klemm, S., McGinnis, L. M., Kathiria, A. S., Mezger, A., Corces, M. R., … Greenleaf, W. J. (2019). Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. Nature Biotechnology.
  
• Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Jabbour, E., Gokbuget, N., Advani, A., Stelljes, M., Stock, W., Liedtke, M., … Kantarjian, H. (2019). Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leukemia Research, 88, 106283.
  
• Cutaneous plasmablastic plasmacytoma. Chung, A., & Liedtke, M. (2019). Cutaneous plasmablastic plasmacytoma. Blood, 134(23), 2116.
  
• Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Saygin, C., Kishtagari, A., Cassaday, R. D., Reizine, N., Yurkiewicz, I., Liedtke, M., … Advani, A. S. (2019). Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Advances, 3(24), 4228–37.
  
• Organ responses with daratumumab therapy in previously treated AL amyloidosis. Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S. L., Lafayette, R. A., … Liedtke, M. (2020). Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Advances, 4(3), 458–66.
  
• Gene Signatures to Distinguish Amyloid Cardiomyopathy Risk in Multiple Myeloma Patients Jha, A., Morgado, I., Lee, D. J., Alexander, K., Tsai, C.-Y., Schimmel, K., … Dangwal, S. (2019). Gene Signatures to Distinguish Amyloid Cardiomyopathy Risk in Multiple Myeloma Patients. CIRCULATION RESEARCH, 125.
  
• Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Ediriwickrema, A., Aleshin, A., Reiter, J. G., Corces, M. R., Köhnke, T., Stafford, M., … Majeti, R. (2020). Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Blood Advances, 4(5), 943–52.
  
• Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience Badar, T., Advani, A. S., Liedtke, M., Arslan, S., Khan, M. A., Aldoss, I., … Atallah, E. (2020). Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(3), S101–S102.
  
• Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Badar, T., Szabo, A., Wadleigh, M., Liedtke, M., Arslan, S., Siebenaller, C., … Atallah, E. (2020). Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Clinical Lymphoma, Myeloma & Leukemia.
  
• Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. Barrett, C. D., Alexander, K. M., Zhao, H., Haddad, F., Cheng, P., Liao, R., … Witteles, R. M. (2020). Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. JACC. Heart Failure.
  
• Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Badar, T., Szabo, A., Advani, A., Wadleigh, M., Arslan, S., Khan, M. A., … Atallah, E. (2020). Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Advances, 4(10), 2308–16.
  
• Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation.
  
• Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. DeAngelo, D. J., Advani, A. S., Marks, D. I., Stelljes, M., Liedtke, M., Stock, W., … O'Brien, S. (2020). Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer Journal, 10(8), 81.
  
• Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone versus standard of care in MAMMOTH. Cornell, R., Hari, P., Tang, S., Biran, N., Callander, N., Chari, A., … Costa, L. (2020). Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone versus standard of care in MAMMOTH. American Journal of Hematology.
  
• Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Stock, W., Martinelli, G., Stelljes, M., DeAngelo, D. J., Gokbuget, N., Advani, A. S., … Kantarjian, H. M. (2020). Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer.
  
• Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Badar, T., Szabo, A., Dinner, S., Liedtke, M., Burkart, M., Shallis, R. M., … Atallah, E. (2020). Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer.
  
• Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., … Kumar, R. (2020). Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(12), 1685–1717.
  
• Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Premkumar, V. J., Lentzsch, S., Pan, S., Bhutani, D., Richter, J., Jagannath, S., … Kapoor, P. (2021). Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal, 11(1), 10.